Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02859688
Other study ID # BRUNO AOI 2014
Secondary ID
Status Completed
Phase N/A
First received August 2, 2016
Last updated August 4, 2016
Start date May 2015

Study information

Verified date July 2016
Source Centre Hospitalier Universitaire Dijon
Contact n/a
Is FDA regulated No
Health authority France: Agence Nationale de Sécurité du Médicament et des produits de santé
Study type Observational

Clinical Trial Summary

Like genetic mutations, DNA methylation anomalies or epimutations can disrupt gene expression and lead to human diseases.

However, unlike genetic mutations, epimutations can in theory be reverted through developmental epigenetic re-programing, which should limit their transmission across generations. Following the request for a parental project of a patient diagnosed with Silver-Russell syndrome (SRS), and the availability of both somatic and spermatozoa DNA from the proband and his father, we had the exceptional opportunity to evaluate the question of inheritance of an epimutation. We provide here for the first time evidence for efficient reversion of a constitutive epimutation in the spermatozoa of an SRS patient, which has important implication for genetic counseling.


Recruitment information / eligibility

Status Completed
Enrollment 7
Est. completion date
Est. primary completion date July 2015
Accepts healthy volunteers No
Gender Male
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Men who have been informed about the study

- Patients over 18 years old

- Fertile

- Matched for age with Silver Russel syndrome (SRS) patients

Exclusion Criteria:

- Adults under guardianship

- Patients without national health insurance cover

- Patients with psychomotor development diseases or pulmonary, cardiac, renal or metabolic diseases (including type 1 and 2 diabetes before the pregnancy), inflammatory and systemic diseases, hypertension, neurological diseases, chronic hepatitis B or C, infection with human immunodeficiency virus (HIV).

Study Design

Observational Model: Family-Based, Time Perspective: Prospective


Related Conditions & MeSH terms


Intervention

Genetic:
pyrosequencing

Methylome


Locations

Country Name City State
France CHU Dijon Bourgogne Dijon

Sponsors (1)

Lead Sponsor Collaborator
Centre Hospitalier Universitaire Dijon

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Analysis of levels of methylation of deoxyribonucleic acid (DNA) measured by cloning/ sequencing and/or pyrosequencing for genes susceptible to imprinting (GSI) Through the study completion up to 1 month No